The problem of anemia treatment in patients with chronic heart failure.

Authors

  • V. P. Ivanov
  • M. O. Kolesnуk
  • O. M. Kolesnуk
  • Ye. I. Ivanovа

DOI:

https://doi.org/10.26641/2307-0404.2018.1(part2).126939

Keywords:

iron deficiency, iron deficiency anemia, anemia of chronic diseases, chronic heart failure, iron supplements, erythropoietin

Abstract

This article presents the literature review devoted to studying the problem of iron-deficient states in the event of chronic heart failure. The epidemiological indicators, various published data on the impact of anemia on the prognosis of chronic heart failure which show a particular urgency of this problem have been presented. All existing approaches to the treatment of iron deficiency anemia and anemia of chronic diseases in this category of patients have been described. The results of studies on the use of classical oral ferrocorrection, as well as the use of modern approaches – intravenous ferrotherapy, isolated and combined use of recombinant human erythropoietin have been demonstrated. The advantages and disadvantages of each of the methods of anemia correction in patients with chronic heart failure have been discussed. The possible reasons for failures in anemia treatment and the absence of a pronounced impact on the clinical manifestations of chronic heart failure with the use of standard approaches to treatment have been discussed as well.

Author Biographies

V. P. Ivanov

National Pirogov Memorial Medical University, Vinnytsya
Department of Internal Medicine N 3

M. O. Kolesnуk

National Pirogov Memorial Medical University, Vinnytsya
Department of Internal Medicine N 3

O. M. Kolesnуk

National Pirogov Memorial Medical University, Vinnytsya
Department of Internal Medicine N 3

Ye. I. Ivanovа

Department of Physical training
Pirogov str., 56, Vinnytsya, 21018, Ukraine

References

Amosova YeN, Sidorova LL, Tsaralunga VN. [Functional state of cardiovascular system in patients with chronic heart failure of coronary genesis and concomitant iron deficiency anemia]. Serce i sudyny. 2011;3:71-80. Ukrainian.

Vertkin AL, Khovasova NO, Laryushkina ED, Sha­maeva KI. [Anemia Guide for practitioners]. Moskva, Eksmo-Press. 2014;144. Russian.

Vygovska YaІ. [Anemia of chronic diseases: pathogenesis, diagnosis, treatment (lecture)]. Ukr Med Chasopys. 2012;6(92):76-79. Ukrainian.

Voronkov LG. [Chronic heart failure in the el­derly: features of pathogenesis, diagnosis and pharma­cotherapy]. Sertse і sudini. 2005;2:89-96. Ukrainian.

Voronkov LG. [Anemia in a patient with CHF: how to evaluate and how to treat?]. Sertseva nedostatnist. 2015;2:5-14. Ukrainian.

Gorodetskiy VV, Godulyan OV. [Iron deficiency and iron deficiency anemia: treatment and diagnosis]. Moskva, Medpraktika-M. 2005;28. Russian.

Gorokhova SG. [Treatment of iron deficient sta­tes. Is everything resolved?]. Russkiy meditsinskiy zhur­nal. 2004;7:1006-9. Russian.

Dziak GV, Pertseva TO,PotabashniiVA, et al. [Anaemia it is a comorbid state].Donetsk, IMA-press. 2013;268. Ukrainian.

Kokolkіna VF. [Juvenile uterine bleeding (metho­dical recommendations)]. Moskva, Izd-vo RGMU. 1998;16. Ukrainian.

Ageev FT, Belenkov YV, Fomin IV, et al. [Prevalence of chronic cardiac failure in the European part of theRussian Federation— data the ERA — HSN]. Serdechnaya nedostatochnost. 2006;3:112-5. Russian.

Ivanov VP,KolesnikMO, Kolesnik OM, et al. [Course peculiarities of chronic heart failure with co­morbid iron deficiency, clinical-prognostic significance of iron deficiency correction]. Kardyolohyia: ot nauky k praktyke. 2015;3(16):61-85. Ukrainian.

Rukavitsyn OA. [Anemia of Chronic Diseases: Some Aspects of Pathogenesis and Correction Path]. Onkogematologiya. 2016;11(1):37-46. Russian.

Smirnova LA.[Iron deficiency anemia in the practice of the therapist] Meditsina. 2004;1:29-31. Russian.

Stuklov NI. [Iron Deficiency and Anemia in Pa­tients with Chronic Heart Failure]. Rational Pharma­cotherapy in Cardiology. 2017;13(5):651-60. Russian.

Comín-Colet J, Ruiz S, Cladellas M, Rizzo M, Torres A, Bruguera JA. A pilot evaluation of the long-term effect of combined therapy with intravenous iron sucrose and erythropoietin in elderly patients with advanced chronic heart failure and cardio-renal anemia syndrome: influence on neurohormonal activation and clinical outcomes. Journal of Cardiac Failure. 2009;15(9):727-35.

Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S. A randomized, controlled trial com­paring IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney International. 2005;68:2846-56.

Rizzo JD, Brouwers M, Hurley P, et al. American Society of Hematology and the American Society of Clinical Oncology Practice Guideline Update Committee American Society of Hematology / American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood. 2010;116(20):4045-59.

Anand IS. Anemia and chronic heart failure im­plications and treatment options. J Am Coll Cardiol. 2008;52(7):501-11.

Drakos SG, Anastasiou-Nana MI, Malliaras KG, Nanas JN. Anemia in chronic heart failure. Congestive Heart Fail. 2009;15:87-92.

Von Haehling S, Anker MS, Jankowska EA, Po­nikowski P, Anker SD. Anemia in chronic heart failure: Can we treat? What to treat? Heart Fail Rev. 2012;17:203-10.

Von Haehling S., Jankowska E.A., Ponikows­ki P., Anker S.D. Anemia in heart failure: an overview of current concepts. Future Cardiology. 2011;7(1):119-29.

Ponikowski P, von Veldhuisen DJ, Comin-Colet J, et al. Benefical effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symp­tomatic heart failure and iron deficiency. Europ. J. Heart Failure. 2015;36(11):657-68.

Ganzoni AM. Intravenous iron dextran: thera­peutic and experiment possibilities. Schweiz Med Wo­chensch. 1970;100:3017303.

Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D. Correction of anemia with epoetin alfa in chronic kidney disease.New EnglandJournal of Medicine. 2006;355:2085-98.

Cullis JO. Diagnosis and management of anaemia of chronic disease: current status. British Journal of Hematology. 2011;154(3):289-300.

Dangsuwan P, Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol. Oncol. 2010;116(3):522-5.

McMurray JJ, Anand IS, Diaz R, Maggioni AP, O'Connor C, Pfeffer MA, Polu KR, Solomon SD, Sun Y, Swedberg K, Tendera M, van Veldhuisen DJ, Wasserman SM, Young JB. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. European Journal of Heart Failure. 2009;11(8):795-801.

Ebner N, von Haehling S. Iron Deficiency in Heart Failure: A Practical Guide. Nutrients. 2013;5(9):3730-9.

Kim YT, Kim SW, Yoon BS, et al. Effect of in­travenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol. Oncol. 2007;105(1):199-204.

Lewis GD, Malhotra R, Hernandez AF, et al. Ef­fect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Frac­tion and Iron Deficiency: The IRONOUT HF Ran­domized Clinical Trial. JAMA. 2017;317(19):1958-66.

Glaspy J, Crawford J, Vansteenkiste J, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br. J. Cancer. 2010;102(2):301-15.

Gonzаlez-Costello J, Comіn-Colet J. Iron defi­ciency and anaemia in heart failure: understanding the FAIR-HF trial. European Journal of Heart Failure. 2010;12(11):1159-62.

Goodnough LT, Nemeth E, Ganz T. Detection, evaluation, and management of iron-restricted ery­thropoiesis. Blood. 2010;116(23):4754-61.

Bolger AP, Bertlett FR, Penston HS, O'Leary J, Pollock N, Kaprielian R, Chapman CM. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. Journal of theAmericanCollegeof Cardiology. 2006;48(6):1225-7.

Toblli JE, Lombrana A, Duarte P, Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. Journal of theAmericanCollegeof Cardiology. 2007;50(17):1657-65.

UsmanovRI, Zueva EB, Silverberg DS, Shaked M. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. Journal of Nephrology. 2008;21(2):236-42.

Cavill I, Auerbach M, Bailie GR, Barrett-Lee P, Beguin Y, Kaltwasser P, Littlewood T, Macdougall IC, Wilson K. Iron and the anaemia of chronic disease: a review and strategic recommendations. Curr. Med. Res. Opin. 2006;22(4):731-7.

National Kidney Foundation Kidney Disease Outcomes Quality Initiative (2007) KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. American Journal of Kidney Diseases. 2007;50(3):471-530.

Mancini DM, Katz SD, Lang C, LaManca J, Hu­daihed A,AndroneAS.Effect of erythropoietin on exer­cise capacity in patients with moderate to severe chronic heart failure. Circulation. 2005;107(2):294-9.

Means RT, Krantz SB. Inhibition of human ery­throid colonyforming units by gamma interferon can be corrected by re-combinant human erythropoietin. Blood. 1991;78:2564-7.

Okonko DO, Grzeslo A, Witkowski T, Man­dal AK, Slater RM, Roughton M, Foldes G, Thum T, Majda J, Banasiak W, Missouris CG, Poole-Wilson PA,AnkerSD, Ponikowski P. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, obser­ver-blinded trial. J Am Coll Cardiol. 2008;51(2):103-12.

Lewis GD, Malhotra R, Hernandez AF, et al. Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Frac­tion and Iron Deficiency: The IRONOUT HF Ran­domized Clinical Trial. JAMA. 2017;317(19):1958-66.

Ponikowski P, Anker SD, Szachniewicz J, Okon­ko D, Ledwidge M, Zymlinski R, Ryan E, Wasserman SM, Baker N, Rosser D, Rosen SD, Poole-Wilson PA, Banasiak W, Coats AJ, McDonald K. Effect of dar­bepoetin alpha on exercise tolerance in anemic patients with symptomatic chronic heart failure. Journal of theAmericanCollegeof Cardiology. 2007;49(7):753-62.

Perlstein TS, Pande R, Berliner N, Vanas­se GJ. Prevalence of 25-hydroxyvitamin D deficiency in sub­groups of elderly persons with anemia: association with anemia of inflammation. Blood. 2011;117(10):2800-6.

Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, Massie BM, Wasserman SM, Tro­tman ML, Sun Y, Knusel B, Armstrong P. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation, 2008;117(4):526-35.

Tarantino G, Brilli E, Zambito Y, Giordano G, Equitani F. Sucrosomial iron: A new highly bioavaible oral iron supplement. Blood. 2015;126(23):4561.

Silverberg D, Wexler D, Palazzuoli A, Iaina A, Schwartz D. The anemia of heart failure. Acta Haema­tologica. 2009;122:109-19.

Wali A, Mushtaq A. Comparative study on ef­ficacy, safety and compliance of intravenous iron sucrose and intramuscular iron sorbitol in iron deficiency anemia of pregnancy. Journal ofPakistanMedical Association. 2002;52(9):392-5.

Downloads

How to Cite

1.
Ivanov VP, Kolesnуk MO, Kolesnуk OM, Ivanovа YI. The problem of anemia treatment in patients with chronic heart failure. Med. perspekt. [Internet]. 2018May4 [cited 2024Nov.19];23(1(part2):34-43. Available from: https://journals.uran.ua/index.php/2307-0404/article/view/126939

Issue

Vol. 23 No. 1(part2) (2018)

Section

CLINICAL MEDICINE

License

Copyright (c) 2018 Medicni perspektivi

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.

Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.